It’s not just drugmakers reshaping the pharmaceutical sector; distributors are rapidly transforming, too. While most investors and policymakers focus on rising prescription drug prices or ...
I rate Doximity a buy with a price target of $65, reflecting a 24% upside due to strong Q2 earnings and favorable industry trends. Doximity's Q2 earnings showed impressive revenue growth, margin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback